Autoimmune pancreatitis not otherwise specified (NOS): Clinical features and outcomes of the forgotten type

Hepatobiliary Pancreat Dis Int. 2019 Dec;18(6):576-579. doi: 10.1016/j.hbpd.2019.05.010. Epub 2019 Jun 11.

Abstract

Background: Autoimmune pancreatitis (AIP) is a well-recognized fibroinflammatory disease of the pancreas. Despite the significant number of studies published on AIP type 1 and 2, no studies have been focused on AIP type not otherwise specified (NOS) and therefore very little is known about clinical features and long-term outcomes of these patients. The aim of this study was to investigate clinical and radiological features of AIP type NOS-patients.

Methods: Patients classified as AIP type NOS at clinical onset included in our database prospectively maintained since 1995 were evaluated. Epidemiological, clinical data were collected and analyzed.

Results: Forty-six patients were included in the study. The clinical onset was mainly characterized by weight loss, jaundice and acute pancreatitis. Eight patients (17.4%) were reclassified as AIP type 2 during follow-up because of the development of ulcerative colitis. Seven patients (15.2%) experienced relapse after steroid treatment but only one (2.2%) needed immunosuppressive drugs because of recurrent relapses.

Conclusions: AIP type NOS shares clinical features similar to AIP type 2 and a relevant proportion of patients was reclassified as AIP type 2 during follow-up because of the development of ulcerative colitis. The risk of relapse is low but not irrelevant.

Keywords: Autoimmune pancreatitis; Follow-up; Not otherwise specified; Outcome; Therapy.

MeSH terms

  • Adult
  • Autoimmune Pancreatitis / diagnosis*
  • Autoimmune Pancreatitis / drug therapy
  • Autoimmune Pancreatitis / epidemiology
  • Colitis, Ulcerative / diagnosis*
  • Colitis, Ulcerative / drug therapy
  • Colitis, Ulcerative / epidemiology
  • Databases, Factual
  • Disease Progression
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Italy / epidemiology
  • Jaundice / diagnosis*
  • Jaundice / drug therapy
  • Jaundice / epidemiology
  • Male
  • Middle Aged
  • Pancreatitis / diagnosis*
  • Pancreatitis / drug therapy
  • Pancreatitis / epidemiology
  • Recurrence
  • Steroids / therapeutic use
  • Time Factors
  • Treatment Outcome
  • Weight Loss*

Substances

  • Immunosuppressive Agents
  • Steroids